1. Scrip
  2. >>COVID-19

Latecomer Merck Enters Coronavirus Vaccine Field With Themis Acquisition

Company Was First To Develop An Ebola Vaccine

 
• By Andrew McConaghie

While Moderna and others frontrunners aim for a 2020 emergency use approval, Merck believes a more deliberate approach will pay off in the long term.

Merck
Merck will acquire Themis, whose vaccine is expected to enter Phase I trials later this year

Merck & Co. Inc. has been conspicuous by its absence to date from the race to develop COVID-19 vaccines and therapies – but has now unveiled a three-part strategy to tackle the pandemic.

This will entail the acquisition of privately held vaccines firm Themis, which already has a novel coronavirus candidate in

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

More from Scrip

Lupin CEO On Trump’s Most Favored Nation Policy, Tariffs, Firm’s Five-Year Plan

 
• By Vibha Ravi

Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.